samedan logo
 
 
spacer
home > epc > summer 2003 > uneasy alliances - managing the relationships in alliances and joint ventures
PUBLICATIONS
European Pharmaceutical Contractor

Uneasy Alliances - Managing the Relationships in Alliances and Joint Ventures

Large pharmaceutical organisations are failing to meet their commitments in terms of shareholder return, and in 2002 an unprecedented number of its major players were forced to issue profit warnings, many for the first time in their history. This has been driven by a number of factors:

Deteriorating R&D productivity
Cost containment by health care providers
Shortening exclusivity periods for compounds in the marketplace
Impending patent expiries in the next few years
Increasing regulatory uncertainty and timelines
Sales force saturation

Of all of these, R&D productivity has perhaps become the most visible problem. Over the last three decades, investment in R&D has risen exponentially from $600 million in the US in 1970 to $24 billion in 1999, whilst the number of NCEs approved by the FDA has actually fallen.

Companies have responded to any pipeline paucity in a number of ways, including mergers, acquisitions, internal process re-engineering, organisational restructuring, partnering with external organisations and a variety of more tenuous methodologies. These have met with varying degrees of success but have not led to the changes the shareholders had been promised, and quite rightly expected.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Grant Coren, Pharmaceutical Practice Leader at Astralis Group Plc

Dr Grant Coren is the Pharmaceutical Practice Leader at Astralis Group plc. For the last 12 years he has specialised in executive search, primarily focused within the pharmaceutical, life science and health care sectors. Grant established his own executive search business, PharmaSearch Ltd, in 1992 and successfully merged this business in 1996 with a US-based Inc500 human resource consultancy firm. He then took up the post of Global Healthcare Practice Leader and Executive Committee member before choosing to return to a more 'hands on' role with Astralis in 2001.

His experience covers all aspects of R&D, new technologies and the commercial aspects of the industry. He has a first degree in Genetics and a PhD in Molecular Biology, and has operated for seven years within academic and clinical research, associated primarily with oncology.
spacer
Dr Grant Coren
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

FT Global Pharmaceutical and Biotechnology Conference 2008

2-3 December 2008, The Cumberland, London

FT Global Pharmaceutical and Biotechnology Conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives,’ feel the pulse’ of the industry, and network with peers across the sector.
More info >>

 
News and Press Releases

Stora Enso with DDSi is Winner of HCPC-Europe Packaging Award 2008

 11th November 2008
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement